During the past decade, Norton Cancer Institute conducted 165 clinical trials. In the 10-year time frame, 165 clinical trials started and 71 clinical trials were completed, i.e. on average, 43% percent of trials that started reached the finish line to date. In the past 5 years, 84 clinical trials started and 46 clinical trials were completed. i.e. 54.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Norton Cancer Institute" #1 sponsor was "Seagen Inc." with 12 trials, followed by "NSABP Foundation Inc" with 11 trials sponsored, "SCRI Development Innovations, LLC" with 11 trials sponsored, "Bristol-Myers Squibb" with 10 trials sponsored and "Hoffmann-La Roche" with 10 trials sponsored. Other sponsors include 173 different institutions and companies that sponsored additional 112 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Norton Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 18 trials as a collaborator, "Merck Sharp & Dohme LLC" with 8 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator and "Bristol-Myers Squibb" with 4 trials as a collaborator. Other collaborators include 68 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Norton Cancer Institute" are "Breast Cancer" (14 trials), "Acute Myeloid Leukemia" (8 trials), "Fallopian Tube Cancer" (8 trials), "Non-Small Cell Lung Cancer" (8 trials) and "Colorectal Cancer" (7 trials). Many other conditions were trialed in "Norton Cancer Institute" in a lesser frequency.

Most popular intervention types in "Norton Cancer Institute" are "Drug" (205 trials), "Biological" (25 trials), "Other" (17 trials), "Radiation" (8 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Gemcitabine" (14 trials), "Carboplatin" (13 trials), "Nivolumab" (13 trials) and "Atezolizumab" (10 trials). Other intervention names were less common.

The vast majority of trials in "Norton Cancer Institute" are 204 trials for "All" genders, 21 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Norton Cancer Institute". undefined are not yet recruiting, 61 are recruiting, 59 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 78 completed trials in Norton Cancer Institute, 1 suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Norton Cancer Institute, 57 "Phase 1" clinical trials were conducted, 109 "Phase 2" clinical trials and 83 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".